CNTA (Centessa Pharmaceuticals plc American Depositary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by CNTA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-24 | Raphael Deferiere | Chief Accounting Officer | D | — | — |
| 2026-06-24 | Mathias Hukkelhoven | Director | D | — | — |
| 2026-06-24 | INDEX VENTURES LIFE VI (JERSEY) L.P. | 10%+ Owner | Sell | — | — |
| 2026-06-24 | Mario Alberto Accardi | Chief Executive Officer | D | — | — |
| 2026-06-24 | IQBAL J HUSSAIN | Chief Legal Officer | D | — | — |
| 2026-06-24 | Gregory M Weinhoff | Chief Business Officer | D | — | — |
| 2026-06-24 | Carol Stuckley | Director | D | — | — |
| 2026-06-24 | ARJUN GOYAL | Director | D | — | — |
| 2026-06-24 | Mary Lynne Hedley | Director | D | — | — |
| 2026-06-24 | Karen M. Anderson | Chief People Officer | D | — | — |
| 2026-06-24 | BRETT I W ZBAR | Director | D | — | — |
| 2026-06-24 | Francesco De Rubertis | Director | D | — | — |
| 2026-06-24 | Stephen Kanes | Chief Medical Officer | D | — | — |
| 2026-06-24 | John J Crowley | Chief Financial Officer | D | — | — |
| 2026-06-24 | Medicxi Ventures I GP Ltd | 10%+ Owner | Sell | — | — |
| 2026-06-24 | Tia L Bush | Chief Technology & Quality Ofc | D | — | — |
| 2026-06-24 | Samarth Kulkarni | Director | D | — | — |
| 2026-05-18 | Mario Alberto Accardi | Chief Executive Officer | F | — | — |
| 2026-03-27 | Karen M. Anderson | Chief People Officer | MIXED | — | — |
| 2026-03-26 | Gregory M Weinhoff | Chief Business Officer | MIXED | — | — |
| 2026-03-18 | Karen M. Anderson | Chief People Officer | MIXED | — | — |
| 2026-03-16 | Karen M. Anderson | Chief People Officer | MIXED | — | — |
| 2026-03-13 | Karen M. Anderson | Chief People Officer | MIXED | — | — |
| 2026-03-13 | Gregory M Weinhoff | Chief Business Officer | Sell | — | — |
| 2026-02-03 | Stephen Kanes | Chief Medical Officer | A | — | — |
| 2026-02-03 | Raphael Deferiere | Chief Accounting Officer | A | — | — |
| 2026-02-03 | Gregory M Weinhoff | Chief Business Officer | MIXED | — | — |
| 2026-02-03 | John J Crowley | Chief Financial Officer | A | — | — |
| 2026-02-03 | Mario Alberto Accardi | Chief Executive Officer | MIXED | — | — |
| 2026-02-03 | Karen M. Anderson | Chief People Officer | MIXED | — | — |
| 2026-02-03 | Tia L Bush | Chief Technology & Quality Ofc | MIXED | — | — |
| 2026-02-03 | IQBAL J HUSSAIN | Chief Legal Officer | MIXED | — | — |
| 2025-12-09 | Mario Alberto Accardi | President, Orexin Program | Sell | — | — |
| 2025-12-08 | Mario Alberto Accardi | President, Orexin Program | MIXED | — | — |
| 2025-11-18 | Tia L Bush | Chief Technology & Quality Ofc | MIXED | — | — |
| 2025-11-18 | IQBAL J HUSSAIN | General Counsel | MIXED | — | — |
| 2025-11-13 | Tia L Bush | Chief Technology & Quality Ofc | MIXED | — | — |
| 2025-11-03 | Mario Alberto Accardi | President, Orexin Program | F | — | — |
| 2025-10-27 | Mario Alberto Accardi | President, Orexin Program | MIXED | — | — |
| 2025-10-16 | IQBAL J HUSSAIN | General Counsel | MIXED | — | — |
| 2025-09-24 | Tia L Bush | Chief Technology & Quality Ofc | MIXED | — | — |
| 2025-09-16 | Mario Alberto Accardi | President, Orexin Program | Sell | — | — |
| 2025-09-15 | IQBAL J HUSSAIN | General Counsel | MIXED | — | — |
| 2025-09-11 | IQBAL J HUSSAIN | General Counsel | MIXED | — | — |
| 2025-09-11 | Mario Alberto Accardi | President, Orexin Program | MIXED | — | — |
| 2025-09-11 | Tia L Bush | Chief Technology & Quality Ofc | MIXED | — | — |
| 2025-08-15 | IQBAL J HUSSAIN | General Counsel | MIXED | — | — |
| 2025-08-01 | Mario Alberto Accardi | President, Orexin Program | F | — | — |
| 2025-07-30 | Mario Alberto Accardi | President, Orexin Program | Sell | — | — |
| 2025-07-25 | Gregory M Weinhoff | Chief Business Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 9,681,818 | — |
| — | Chief Innovation Officer | 990,290 | — |
| — | EVP & Chairman of Development | 783,066 | — |
| — | Chief Executive Officer | 259,017 | — |
| — | 10%+ Owner | 236,108 | — |
| — | 10%+ Owner | 236,108 | — |
| — | Chief Administrative Officer | 232,007 | — |
| — | Chief Technology Officer | 188,244 | — |
| — | Chief Medical Officer | 165,000 | — |
| — | 10%+ Owner | 93,526 | — |
| — | 10%+ Owner | 93,526 | — |
| — | SVP Regulatory Affairs | 66,892 | — |
| — | Director | 60,000 | — |
| — | Chief Accounting Officer | 53,101 | — |
| — | Chief Technology & Quality Ofc | 3,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CNTA quote page; the site-wide leaderboard is on the insider transactions hub.